,i #aahth ,,congress #ast ,session ,h4 ,r4 #fjid ,,in ,,the ,,house ,,of ,,representatives ,october #bf1 #bjbc ,ms4 ,matsui 7for herself1 ,mr4 ,dunn of ,florida1 ,mr4 ,thompson of ,california1 and ,mr4 ,kelly of ,pennsylvania7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committee on ,ways and ,means1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend titles ,,xviii and ,,xix of the ,social ,security ,act and title ,,xxvii of the ,public ,health ,service ,act to refine the set of information sources for determining coverage of certain drugs and biologicals used in the treatment or management of a rare disease or condition1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,providing ,realistic ,opportunity ,to ,equal and ,comparable ,treatment for ,rare ,act or the ,,protect ,rare ,act4 #b4 ,coverage of certain drugs used in treatment or management of rare disease or condition 7a7 ,medicare 7#a7 ,in general ,section #ahfa7t77#b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciex7t77#b77 is amended-- 7,a7 in subparagraph 7,a71 by inserting after regimen the following3 1 or in the treatment or management of a disease or condition affecting #bjj1jjj or fewer individuals in the ,united ,states12 and 7,b7 in subparagraph 7,b77ii7-- 7i7 in subclause 7,i71 by striking 1 or at the end and inserting a semicolon2 7ii7 in subclause 7,,ii71 by striking the period at the end and inserting 2 or2 and 7iii7 by adding at the end the following new subclause3 7,,iii7 in the case of a drug that is used in the treatment or management of a disease or condition affecting #bjj1jjj or fewer individuals in the ,united ,states1 such use is supported by peer-reviewed medical literature1 including clinical guidelines1 and is not reviewed unfavorably in the compendia described in section #aibg7;g77#a77;,b77i71 or listed as a contraindication in the ,,fda-approved labeling4 4 7#b7 ,medically accepted uses of covered part d drugs in treating rare conditions ,section #ahfj;,d-#b7;e77#d77;,a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajb7;e77#d77;,a77 is amended-- 7,a7 in clause 7i77,,ii71 by striking and2 7,b7 by redesignating clause 7ii7 as clause 7iii72 and 7,c7 by inserting after clause 7i77,,ii7 the following new clause3 7ii7 in the case of a covered part ,d drug used in the treatment or management of a disease or condition affecting #bjj1jjj or fewer individuals in the ,united ,states1 in section #ahfa7t77#b77;,b72 and 4 7#c7 ,effective date ,the amendments made by this subsection apply with respect to items and services furnished on or after the date that is #cj days after the date of the enactment of this ,act4 7b7 ,medicaid 7#a7 ,in general ,section #aibg7k77#f7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7k77#f77 is amended to read as follows3 7#f7 ,medically accepted indication ,the term medically accepted indication means any use for a covered drug-- 7,a7 which is approved under the ,federal ,food1 ,drug1 and ,cosmetic ,act2 7,b7 which is supported by one or more citations included or approved for inclusion in any of the compendia described in subsection 7g77#a77;,b77i72 or 7,c7 in the case of a drug used to treat or manage a disease or condition affecting #bjj1jjj or fewer individuals in the ,united ,states-- 7i7 the use of such drug is supported by peer-reviewed medical literature1 including clinical guidelines2 and 7ii7 is not reviewed unfavorably in the compendia described in subsection 7g77#a77;,b77i71 or listed as a contraindication in the ,,fda-approved labeling4 4 7#b7 ,conforming amendment ,section #aibg7;d77#d77;,c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7;d77#d77;,c77 is amended by striking compendia and inserting sources4 7#c7 ,effective date ,the amendments made by this subsection apply with respect to covered outpatient drugs furnished on or after the date that is #cj days after the date of the enactment of this ,act4 7c7 ,private health insurance 7#a7 ,in general ,subpart ,,ii of part ,a of title ,,xxvii of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg-#ai7 is amended by adding at the end the following new section3 #bgcj4 ,expedited processes for review associated with certain drugs used in treatment or management of a rare disease or condition ,a group health plan or a health insurance issuer offering group or individual health insurance coverage shall provide a mechanism for expedited formulary exception1 reconsideration1 and appeal of any denial of coverage for a drug or biological-- 7#a7 approved by the ,food and ,drug ,administration2 7#b7 for which the use is related to treatment or management of a disease or condition affecting #bjj1jjj or fewer individuals in the ,united ,states2 and 7#c7 the use of which is supported by the ,,fda-approved label or peer-reviewed literature1 including clinical guidelines1 and that is not reviewed unfavorably in the compendia described in section #aibg7;g77#a77;,b77i77 of the ,social ,security ,act or listed as a contraindication in the ,,fda-approved labeling4 4 7#b7 ,effective date ,the amendment made by this subsection applies with respect to plan years beginning on or after the date that is #cj days after the date of the enactment of this ,act4